文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

成人间质性肺病合并无高碳酸血症急性呼吸衰竭:何时使用经鼻高流量氧疗?

Adults with interstitial lung disease and acute respiratory failure without hypercapnia: when should high flow nasal oxygen be used?
PubMed 文献 · Emerg Med J · 2025-11-21
一句话结论在间质性肺病合并无高碳酸血症急性呼吸衰竭成人中,经鼻高流量氧疗未显著改善死亡率,但可能有助于症状管理。

本文综述评估了在间质性肺病(ILD)合并无高碳酸血症急性呼吸衰竭(ARF)成人中,经鼻高流量氧疗(HFNO)是否优于传统氧疗(COT)以改善症状和全因死亡结局。检索1975年至2025年6月20日的Medline、EMBASE和Cochrane Library,鉴定2362篇论文,17篇全文审查,最终纳入2篇系统评价。两篇系统评价均未发现HFNO较COT显著改善死亡率;HFNO组中位生存21.0天(95%CI 13.0-61.0),COT组133天(95%CI 26.0-374.0,p=0.1323);HFNO住院死亡率26.5%-59.1%。一篇综述报告HFNO组死亡与临终质量评分数值上优于COT组(4.58±0.67 vs 4.09±0.96)。证据有限,HFNO可能有益于症状管理,但死亡率仍高,试验时需与患者及家属审慎沟通。

要点

  • 在ILD合并无高碳酸血症ARF成人中,两篇系统评价均未发现HFNO较COT显著改善死亡率。
  • HFNO组中位生存21.0天(95%CI 13.0-61.0),COT组133天(95%CI 26.0-374.0,p=0.1323)。
  • HFNO住院死亡率范围为26.5%至59.1%。
  • 一篇综述报告HFNO组死亡与临终质量评分数值上优于COT组(4.58±0.67 vs 4.09±0.96)。
  • 证据有限提示HFNO可能有益于症状管理;死亡率仍高,试验时需与患者及家属审慎沟通。

适用人群与场景

  • 成人间质性肺病(ILD)合并无高碳酸血症的急性呼吸衰竭(ARF)患者。

研究设计与关键结果

  • 研究类型:综述,检索Medline、EMBASE和Cochrane Library(1975年至2025年6月20日),鉴定2362篇论文,17篇全文审查,纳入2篇系统评价。
  • 两篇系统评价均未发现HFNO较COT显著改善死亡率。
  • HFNO组中位生存21.0天(95%CI 13.0-61.0),COT组133天(95%CI 26.0-374.0,p=0.1323)。
  • HFNO住院死亡率范围为26.5%至59.1%。
  • 一篇综述报告HFNO组死亡与临终质量评分数值上优于COT组(4.58±0.67 vs 4.09±0.96)。

证据类型、等级与局限

  • 证据类型:综述,纳入2篇系统评价。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 证据有限提示HFNO可能有益于ILD合并无高碳酸血症ARF患者的症状管理。
  • HFNO使用时死亡率仍高,作者认为在ARF情况下试用HFNO时需与患者及家属审慎沟通。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Interstitial lung diseases (ILDs) represent a heterogenous group of disorders affecting the lung parenchyma. Patients with ILD are frequently admitted to hospital secondary to respiratory decompensation which can result in acute respiratory failure (ARF). High flow nasal oxygen (HFNO) has increasingly been used in other causes of ARF following the recommendations of the European Respiratory Society. A review was undertaken to evaluate the question: in adults with ILD and ARF without hypercapnia, is HFNO better than conventional oxygen therapy (COT) at reducing symptoms and all-cause mortality outcomes? Medline via PubMed, EMBASE via OVID and the Cochrane Library were searched between 1975 and 20 June 2025. 2362 papers were identified with 17 undergoing full-text review. Two systematic reviews met inclusion criteria and directly answered the three-part question. Study information, participant demographics, key results and study weaknesses were established for each paper. Neither systematic review found HFNO improved mortality outcomes, when compared with COT, to a statistically significant threshold for patients with ILD with ARF. Reported median survival with HFNO use was 21.0 days (95% CI 13.0 to 61.0) and COT use 133 days (95% CI 26.0 to 374.0, p=0.1323). Inpatient mortality with HFNO use ranged between 26.5% and 59.1%. Symptomatically, one review reported a numerical improvement in the Quality of Death and Dying Score for the HFNO group versus the COT group (4.58 ± 0.67 vs 4.09 ± 0.96). There is limited evidence to suggest that HFNO improves mortality outcomes for patients with ILD in ARF. However, it may be beneficial for symptom management. Mortality remains high despite HFNO use, thus careful discussions with patients and their relatives are required should a trial be used in the setting of ARF.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. White L, Ellam M, Hickman R, et al. Adults with interstitial lung disease and acute respiratory failure without hypercapnia: when should high flow nasal oxygen be used? Emerg Med J. 2025. PMID: 41271401. doi:10.1136/emermed-2025-215112

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。